uniQure’s (QURE) Buy Rating Reaffirmed at Guggenheim

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating restated by stock analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports.

A number of other equities analysts have also commented on QURE. Cantor Fitzgerald raised their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. StockNews.com raised shares of uniQure to a “sell” rating in a report on Wednesday. Royal Bank of Canada boosted their price objective on uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday. The Goldman Sachs Group lowered their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of uniQure in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $28.33.

uniQure Stock Up 1.5 %

uniQure stock traded up $0.23 during midday trading on Wednesday, reaching $15.53. The stock had a trading volume of 3,071,166 shares, compared to its average volume of 1,624,749. uniQure has a 1-year low of $3.73 and a 1-year high of $17.39. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm’s fifty day simple moving average is $6.42 and its 200-day simple moving average is $6.15. The stock has a market capitalization of $756.93 million, a P/E ratio of -3.06 and a beta of 0.89.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, analysts expect that uniQure will post -3.74 EPS for the current fiscal year.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. abrdn plc grew its position in shares of uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after buying an additional 1,528,581 shares during the period. Franklin Resources Inc. purchased a new stake in uniQure in the third quarter worth approximately $7,360,000. Point72 Asset Management L.P. lifted its stake in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares in the last quarter. FMR LLC grew its position in shares of uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in shares of uniQure in the second quarter worth about $815,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.